EUVIMEDEUVIMED entdecken
Crossref

Astragali radix Against Colorectal Cancer: Network Pharmacology, Molecular Docking, and In Vitro/In Vivo Validation of PI3K ‐Akt Pathway Modulation

Zhaohuan Li iD, Jianjin Guo iD, Mingbin Gui iD, Jie Xu iD, Jingwen Zhao iD, Xin Zhang iD, Yansheng Zhang iD, Zijie Yang iD, Zengqiang Yang iD, Feng Gao iD

Phytotherapy Research · 2026-06 · 40 (6) · 3317-3335

DOI: 10.1002/ptr.70224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 27.03.2026. Verfasst von Zhaohuan Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins c-akt, Drugs, Chinese Herbal, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Gansu Provincial Natural Science Foundation, Gansu Provincial Youth Science and Technology Fund, Lanzhou Municipal Science and Technology Bureau Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) exhibits high incidence and mortality rates, and current therapeutic approaches remain limited, underscoring the urgent need for novel treatment strategies. Astragali Radix , a traditional Chinese medicine with diverse pharmacological properties, has shown potential in cancer therapy; however, its anti‐CRC mechanisms remain poorly understood. This study investigated the active components of A. Radix and their anti‐CRC mechanisms using an integrated approach combining network pharmacology, molecular docking, and in vitro and in vivo experiments. Twenty active components of A. Radix with high oral bioavailability and drug‐likeness were screened from databases, and relevant networks were constructed to identify core targets, including SRC, PIK3CA, and AKT1. Enrichment analysis revealed that these targets are primarily involved in the regulation of the PI3K‐Akt signaling pathway. Molecular docking confirmed strong binding affinity between the active components of A. Radix and the core targets. In vitro experiments on HCT 116 and HT 29 cells demonstrated that A. Radix and quercetin inhibited cell proliferation in a concentration‐ and time‐dependent manner, downregulating the mRNA expression of key genes ( PIK3CA , PIK3R1 , AKT1 ) in the PI3K‐Akt pathway, and A. Radix showed superior efficacy compared with quercetin. Western blot analysis confirmed that the protein levels of PI3K, p‐PI3K, AKT, p‐AKT, PIK3CA, PIK3R1, and AKT1 were reduced in A. Radix ‐treated cells, as were the ratios of p‐PI3K/PI3K and p‐AKT/AKT. In vivo experiments on MC38 tumor‐bearing mice further revealed that A. Radix significantly suppressed tumor growth and reduced pathway‐related protein levels, outperforming quercetin. Additionally, acute toxicity experiments confirmed the favorable safety profile of A. Radix . This study demonstrates that A. Radix inhibits tumor cell proliferation through multi‐component targeting of the PI3K‐Akt signaling pathway, providing new therapeutic targets and theoretical evidence for CRC treatment. Furthermore, it establishes a methodological framework for the modern investigation of traditional Chinese medicine formulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProto-Oncogene Proteins c-aktDrugs, Chinese HerbalPhosphatidylinositol 3-KinasesAntineoplastic Agents, PhytogenicHumansMolecular Docking SimulationNetwork PharmacologyAnimalsSignal TransductionCell ProliferationMiceQuercetinHCT116 CellsHT29 CellsMice, NudeClass I Phosphatidylinositol 3-KinasesAstragalus PlantAstragalus propinquus

Stichwörter der Autor:innen

Astragali radixPI3K‐Akt signaling pathwaycolorectal cancerin vitro and in vivo mechanismsmolecular dockingnetwork pharmacology

Substanzen

Proto-Oncogene Proteins c-aktDrugs, Chinese HerbalPhosphatidylinositol 3-KinasesQuercetinHuang QiAntineoplastic Agents, PhytogenicClass I Phosphatidylinositol 3-KinasesPIK3CA protein, human

Autor:innen und Institutionen

  • School of Clinical Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, China.
  • Department of Colorectal and Anal Surgery, Gansu Provincial Central Hospital, Lanzhou, China.
  • State Key Laboratory of Natural Product Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China.
  • Department of Colorectal and Anal Surgery, The 940th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army, Lanzhou, China.
  • Department of Hepatobiliary and Pancreatic Surgery I, The First Hospital of Jilin University, Changchun, China.
  • Department of Colorectal and Anal Surgery, Xi'an Hospital of Traditional Chinese Medicine, Xi'an, China.

ORCID-Profile: Zhaohuan Li, Jianjin Guo, Mingbin Gui, Jie Xu, Jingwen Zhao, Xin Zhang, Yansheng Zhang, Zijie Yang, Zengqiang Yang, Feng Gao

Förderung

  • Gansu Provincial Natural Science Foundation
  • Gansu Provincial Youth Science and Technology Fund
  • Lanzhou Municipal Science and Technology Bureau Project
  • Natural Science Foundation of Gansu Province

Zitieren

APA

Li, Z., Guo, J., Gui, M., Xu, J., Zhao, J., Zhang, X., Zhang, Y., Yang, Z., Yang, Z., & Gao, F. (2026). Astragali radix Against Colorectal Cancer: Network Pharmacology, Molecular Docking, and In Vitro/In Vivo Validation of PI3K ‐Akt Pathway Modulation. Phytotherapy Research, 40(6), 3317-3335. https://doi.org/10.1002/ptr.70224

Vancouver

Li Z, Guo J, Gui M, Xu J, Zhao J, Zhang X, et al. Astragali radix Against Colorectal Cancer: Network Pharmacology, Molecular Docking, and In Vitro/In Vivo Validation of PI3K ‐Akt Pathway Modulation. Phytotherapy Research. 2026;40(6):3317-3335. doi:10.1002/ptr.70224

BibTeX
@article{Li2026,
  author = {Li, Zhaohuan and Guo, Jianjin and Gui, Mingbin and Xu, Jie and Zhao, Jingwen and Zhang, Xin and Zhang, Yansheng and Yang, Zijie and Yang, Zengqiang and Gao, Feng},
  title = {Astragali radix Against Colorectal Cancer: Network Pharmacology, Molecular Docking, and In Vitro/In Vivo Validation of PI3K ‐Akt Pathway Modulation},
  journal = {Phytotherapy Research},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {3317--3335},
  doi = {10.1002/ptr.70224}
}
Kostenlos starten →